Compare MYSZ & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | PFSA |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 1.0M |
| IPO Year | 2017 | 2021 |
| Metric | MYSZ | PFSA |
|---|---|---|
| Price | $1.37 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 681.7K | ★ 2.7M |
| Earning Date | 11-13-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,000.00 | $100,000.00 |
| Revenue This Year | $38.86 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.33 | $0.05 |
| 52 Week High | $4.28 | $28.32 |
| Indicator | MYSZ | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 22.57 | 38.42 |
| Support Level | $0.37 | $0.89 |
| Resistance Level | $2.60 | $24.50 |
| Average True Range (ATR) | 0.14 | 0.42 |
| MACD | 0.55 | 0.35 |
| Stochastic Oscillator | 2.18 | 2.88 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.